Radioimmunotherapy of B-Cell Lymphoma with [131I]Anti-B1 (Anti-CD20) Antibody

• Published in: The New England journal of medicine Vol. 329; no. 7; pp. 459 - 465
• Main Authors: Kaminski, Mark S, Zasadny, Kenneth R, Francis, Isaac R, Milik, Adam W, Ross, Charles W, Moon, Scott D, Crawford, Shelley M, Burgess, Jeanne M, Petry, Neil A, Butchko, Gregory M, Glenn, Stephan D, Wahl, Richard L
• Format: Journal Article
• Language: English
• Published: Boston, MA Massachusetts Medical Society 12.08.1993
• Subjects: Adult; Aged; Antibodies, Monoclonal - therapeutic use; Antigens; Antigens, CD - immunology; Antigens, CD20; Antigens, Differentiation, B-Lymphocyte - immunology; B-cell lymphoma; Biological and medical sciences; Bone marrow; Cancer therapies; CD20 antigen; Chemotherapy; Chromatography; Dosimetry; Drug dosages; Hematologic and hematopoietic diseases; Hematology; Humans; Immunoglobulins; Internal medicine; Iodine Radioisotopes - therapeutic use; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Lymphocytes B; Lymphoma; Lymphoma, B-Cell - diagnostic imaging; Lymphoma, B-Cell - radiotherapy; Male; Medical sciences; Middle Aged; Monoclonal antibodies; Myelosuppression; Patients; Radiation Dosage; Radioactivity; Radioimmunotherapy; Radioisotopes; Radionuclide Imaging; Remission; Human; Malignant hemopathy; Treatment; Monoclonal antibody; Lymphoma; Immunotherapy
• ISSN: 0028-4793; 1533-4406
• DOI: 10.1056/NEJM199308123290703

Despite the use of various combined chemotherapeutic regimens for advanced-stage intermediate- and high-grade lymphomas, roughly half of patients treated do not have a complete remission or eventually have a relapse after a remission. This situation has not improved noticeably in almost two decades 1 , 2 . Treatment with standard-dose salvage chemotherapy rarely results in durable remissions and often has serious toxicity. Although the use of high-dose chemotherapy with bone marrow transplantation has shown promise, not all patients derive long-term benefit from this treatment 3 . Furthermore, a curative treatment for patients with advanced low-grade lymphoma still remains to be clearly established 4 . . . .